DBV Technologies S.A.

DBV Technologies is a clinical-stage biopharmaceutical company that develops epicutaneous immunotherapy treatments using a skin patch platform called Viaskin. The technology delivers microgram amounts of antigens through intact skin to activate immune cells without entering the bloodstream. The company's primary candidate is the Viaskin Peanut patch, which is evaluated for treating peanut allergies in toddlers and children. Additionally, the firm develops earlier-stage product candidates, including Viaskin Milk for cow's milk allergy and eosinophilic esophagitis. Its intended end users are pediatric patients suffering from severe food allergies, supported by parents, caregivers, allergists, and pediatricians.

The company conducts clinical research globally, evaluating hundreds of pediatric participants across multiple Phase 2 and Phase 3 clinical trials. Its clinical development and regulatory pursuits focus on the United States and the European Union. The text also references patient survey data gathered across eight European countries. The provided text does not disclose the company's headquarters.

Summary of the business section of DBV Technologies's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.